RxDoctor Payments Data

Lori Wyatt, MD

Family Medicine · Greenville, TXNPI 1043570302

Payments from drug & device makers

$1,159in general payments, 2019–2025

Across 73 payments — averaging $15.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$205
  • Pfizer$179
  • Novo Nordisk$178
  • Abbott$109
  • Exact Sciences$108
  • Eitan Medical North America, Inc.$100
  • plus $279 from 10 others

What the payments were for

  • Food & beverage$1,15399%
  • Education$61%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca14$205
Pfizer14$179
Novo Nordisk14$178
Abbott5$109
Exact Sciences6$108
Eitan Medical North America, Inc.1$100
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC5$68
Lilly USA, LLC4$61
GSK2$42
Merck2$27
Nevro Corp.1$17
Circassia Inc.1$15
Boehringer Ingelheim1$14
Novartis1$11
Amgen1$11
Amarin Pharma, Inc.1$11

How this compares

$1,159 in reported general payments places this provider in the 60th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$29,523
Medicare patients
171
Services billed
419

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin73$73,586
OzempicSemaglutide38$52,588
TrulicityDulaglutide19$30,496
FarxigaDapagliflozin Propanediol32$27,485
EliquisApixaban34$24,392
JanuviaSitagliptin Phosphate21$21,830
LinzessLinaclotide15$12,942
XareltoRivaroxaban15$12,578
MounjaroTirzepatide12$12,199
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$12,153
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$3,303
Atorvastatin Calcium306$2,917
Omeprazole132$2,255
Duloxetine Hcl60$2,048
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$2,014

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$14$73,58673 claims
Novo NordiskOzempic$178$52,58838 claims
Lilly USA, LLCTrulicity, Mounjaro$61$42,69531 claims
AstraZenecaFarxiga$205$27,48532 claims
PfizerEliquis$179$24,39234 claims
MerckJanuvia$27$21,83021 claims
GSKTrelegy Ellipta$42$12,15314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Greenville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →